PT-141, known by its FDA-approved brand name Vyleesi, stands out in this guide series as one of the few peptides discussed on this site that reached full FDA approval through the standard drug development pathway.
What It Is
Bremelanotide is a synthetic peptide that activates melanocortin receptors in the brain, specifically MC4R, which are involved in regulating sexual desire, among other functions. Unlike GLP-1 drugs, which act primarily on metabolic pathways, bremelanotide works through a central nervous system mechanism.
Regulatory Status
Bremelanotide was FDA-approved in 2019, under the brand name Vyleesi, specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a self-injection used on an as-needed basis before anticipated sexual activity, distinct from the daily or weekly dosing common to many other peptide drugs.
What the Research Shows
Approval was based on Phase 3 trials demonstrating improvement in sexual desire and reduction in distress related to low desire, compared to placebo, in the specific approved population. As with the GLP-1 drugs covered elsewhere on this site, this approval reflects a full clinical trial program rather than preliminary or animal-only research.
Common Side Effects
Nausea is the most commonly reported side effect, along with flushing, headache, and injection site reactions. A notable and specific effect is transient darkening of the skin and gums in a subset of patients, related to its action on melanocortin receptors, which is disclosed on the drug's label. It's contraindicated in patients with uncontrolled high blood pressure or known cardiovascular disease due to effects on blood pressure.
The Bottom Line
Bremelanotide is a useful reference point precisely because it shares chemical ancestry with less-studied melanocortin peptides like Melanotan II, while having actually completed the full trial and approval process for a specific, defined use. That contrast is a clear illustration of how much daylight exists between compounds that sound similar but have very different evidence behind them.
Why It's a Useful Reference Point
Because bremelanotide shares its melanocortin-receptor mechanism with Melanotan II, discussed elsewhere in this guide series, but actually completed FDA trials and approval, it's a useful direct illustration of how two chemically related peptides can end up in completely different evidence and regulatory positions depending on whether one was actually taken through the full clinical trial process.
Dosing and Administration in Practice
Unlike the daily or weekly dosing schedules common to most other peptides on this site, bremelanotide is used on an as-needed basis, self-injected at least 45 minutes before anticipated sexual activity, with a maximum recommended frequency and a required waiting period between doses specified on its label, based on the trial data establishing both its effective use pattern and its safety limits.